Navigation Links
New tetanus-diphtheria combination vaccine launched by Serum Institute of India

A combination vaccine for immunization against tetanus and diphtheria, Td-Vac priced at Rs. 7.50 has been launched by Serum Institute of India // .

The vaccine is aimed at combating the fatal tetanus and diphtheria (Td) in adolescents and adults. It is much different than the currently existing dual antigen vaccine used in children and would be used as an alternative to the TT (Tetanus vaccine), commonly administered following injury.

The vaccine is regarded to be very cost effective as it offers dual protection against both diphtheria and tetanus. The cost is much lesser than the existing Tetanus (TT) vaccine, given at Rs 6.50 per dose.

The vaccine has been launched in just the right time in India, where there is rise in the incidence of Diphtheria. Infact the number of new cases has doubled over the previous year. The disease, which is most common in areas with poor sanitation, has a mortality rate of nearly 20%.

Tetanus, a vaccine preventable disease is caused by infection with Clostridium tetanii, a bacteria that gains access to the human body through an open wound. Approximately one-half of all individuals between 21-30 years of age and 82 per cent of those over 30 years of age are susceptible to this disease.

The launch of the tetanus-diphtheria vaccine is said to be significant following the rule of the US government according to which the vaccination has been has made mandatory for every person traveling to the country.

The usage of the Td vaccine, more specifically in pregnant women has already been implemented in countries such as the USA. It is recommended that the vaccine be used in all individuals above 7 years of age by The Indian Academy of Pediatrics (IAP).


'"/>




Page: 1

Related medicine news :

1. The bad combination
2. Warding off symptoms of premenstrual syndrome by combination therapy
3. Cholesterol can be lowered using combination of Soy Proteins and Sterols
4. Nanocells cancer combination therapy acts as chemotherapy as well as anti-angiogenic drug
5. Calcitriol [Vitamin D] with combination of painkillers for cancer treatment
6. Chloroquine and Primaquine combination Malarial drug for resistant parasites.
7. Eloxatin combination reduces bowel cancer recurrences
8. Death from heart attack can be reduced by new drug combination
9. More effective Antiretroviral HIV drug combination
10. Salmeterol - to be used in combination & only when required
11. New chemo combination to fight breast cancer better

Post Your Comments:
(Date:11/27/2009)...SUR-SEINE,France,Nov.27/PRNewswire/--TeamGarmin-Sl...dicatedtoethicalsportinganddevelopingthenextgenera...omeTeamGarmin-TransitionswiththeadditionofTransiti...listheworld,sleadingmanufacturerofadaptiveeyewear,...widestselectionofspectaclelensessuchasTransitionsl...
(Date:11/27/2009)... bring unprecedented medical, economic burdens, st...Day News) -- The number of people with diabetes in...next 25 years, a new study predicts. , That wou...eople with the disease, up from 23.7 million today...ple with diabetes will triple, the study also warn...
(Date:11/27/2009)... Specialist manufacturers who use medical...ing millions of dollars by bringing in technology ...asing numbers of pro-active medical manufacturers ...ncept stage of their projects, ensuring that progr...cesses or potentially outdated technology. , ...
(Date:11/26/2009)... years, the number of Americans living with diabet...n in 2009 to 44.1 million in 2034. Over the same p...sing from $113 billion to $336 billion, even with ...ers based at the University of Chicago report in t...er of those with diabetes covered by Medicare will...
(Date:11/26/2009)... No more letters from the North Pole, Tex...ext messages from Santa , ...e operational efficiencies at the North Pole Santa...hildren all over the globe informed of his Christm...rsquo;s research department have identified a larg...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2
...al Systems (NYSE: VAR ) announced today that it ...ar 2009 following the close of regular trading on ... be followed by a teleconference available to all ...formation on the conference call webcast will be a...
...rvices are not being provided in Zimbabwe. The pub...her communicable diseases are rampant. Staggering ...ges of food and fuel. Estimates are that 300,000 p...ak has claimed over 600 lives. , , InterActi...
...treatment, elective procedures, study says , ...could be a shortage of 1,300 general surgeons in t...shortage could increase to 6,000 by 2050, a new Oh...y departments. A shortage of general surgeons mean...
...anical Council (ABC) has officially launched its A... http://www.themeaningoftea.com ) adoption of tea ...ea Dragon Films will provide ABC financial support...ase, one of the most robust and powerful herbal da...
...e will feature two of the most innovative new voic...Activism Week and Personhood Conference Jan. 21-23.../prnh/20081105/DC44231LOGO ) , , The TAW will...d Lila Rose, the UCLA student president of Live ...
...evelop the disease within 5 years, study finds , ...ong people whose brain scans show signs of multipl...ll develop MS within about five years, researchers...lities similar to those that occur in MS. After th...
Other Medicine News:Health News:Varian Medical Systems Schedules First Quarter FY2009 News Release and Conference Call 2Health News:Varian Medical Systems Schedules First Quarter FY2009 News Release and Conference Call 3Health News:U.S. May Soon Face Shortage of General Surgeons 2Health News:Tea Dragon Films is First Adopter in the American Botanical Council's New Adopt-An-Herb Program 2Health News:Tea Dragon Films is First Adopter in the American Botanical Council's New Adopt-An-Herb Program 3Health News:Tea Dragon Films is First Adopter in the American Botanical Council's New Adopt-An-Herb Program 4Health News:A.L.L. Personhood Conference Features Pro-Life New Media Stars 2Health News:MRI Can Spot Presymptomatic MS 2
(Date:11/25/2009)....25/PRNewswire/-- ChemoCentryx,Inc.,announcedtoda...T-1(theProspectiveRandomizedOralTherapyEvaluationi...patientswithmoderate-to-severeCrohn,sdiseasedemons...abilityprofile.Thestudydemonstratedevidenceofclini...dasa70-pointdecreaseintheCrohn,sDiseaseActivityInd...
(Date:11/24/2009)...ewswire-FirstCall/--QuestDiagnosticsIncorporated(N...sting,informationandservices,announcedthatitissche...onferenceinNewYorkCity.Thepresentationisscheduledf..., Duringtheconference,thecompanywillreaffirmits...ingincometoexceed18%ofrevenues,anddilutedearningsp...
(Date:11/24/2009)...wswire/--Inadditiontofamily,friendsandhealth,cance...herThanksgivinggratitudelist. ,, "Theyheardthef...aidofMonday,sverdictstotaling$103millionindamagesa...2,000womennationwidewhohavesuedWyethandPfizerpharm...ndPrempro.Wisneskiandtheothervictimsofhormonethera...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2Maryland Woman Thankful for Wyeth Verdicts 2Ovarian Cancer Coalition Partners With Consuelo Vanderbilt Costin 56921 1Ovarian Cancer Coalition Partners With Consuelo Vanderbilt Costin 56921 2Air Quality Sciences Achieves Re Accreditation as the US Indoor Air Quality Testing Partner for Europes Coveted Blue Angel Program 56918 1Air Quality Sciences Achieves Re Accreditation as the US Indoor Air Quality Testing Partner for Europes Coveted Blue Angel Program 56918 2Air Quality Sciences Achieves Re Accreditation as the US Indoor Air Quality Testing Partner for Europes Coveted Blue Angel Program 56918 3AOBO Launches New OTC Product to Treat Throat Inflammation 14001 1AOBO Launches New OTC Product to Treat Throat Inflammation 14001 2
...al , AUSTIN, Texas--(BUSINESS WIRE)--May 30, 2007-...ed today the publication of,data describing the dr...n in a patient with a rare inherited form of cance...isorder characterized by,inherited mutations in th...orted treatment of Li-Fraumeni tumors with a thera...
...2007 - Gilead,Sciences, Inc. (Nasdaq:GILD) today a...udy of aztreonam lysine for inhalation for,the tre...e,pulmonary Pseudomonas aeruginosa (P. aeruginosa)...y 28 from baseline in respiratory,symptoms, as ass...,(CFQ-R), a patient-reported outcome (PRO) tool us...
Other Medicine Technology:Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 2Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 3Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 4Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 2Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 3Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 4Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 5
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
Medicine Products: